BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-10
220 industry Phase 2/3 trial readout(s) and 44 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P1/P2 | Sernova Biotherapeutics Inc. | NCT03513939 A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation | Type 1 Diabetes Mellitus | active not recruiting | 17 |
| 2026-10 est. | P3 | Eli Lilly and Company LLY | NCT04088396 A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) | Systemic Juvenile Idiopathic Arthritis | active not recruiting | 58 |
| 2026-10 est. | P1/P2 | Immunocore Ltd IMCR | NCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Select Advanced Solid Tumors | active not recruiting | 410 |
| 2026-10 est. | P2 | Vyriad, Inc. | NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Melanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Cancer | active not recruiting | 87 |
| 2026-10 est. | P1/P2 | Laminar Pharmaceuticals | NCT04299191 Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | High-grade Glioma; Solid Tumor, Unspecified, Child | recruiting | 28 |
| 2026-10 est. | P1/P2 | Philogen S.p.A. | NCT04443010 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma | Glioblastoma | recruiting | 226 |
| 2026-10 est. | P3 | Inmunotek S.L. | NCT04898283 Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. | Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic | recruiting | 180 |
| 2026-10 est. | P1/P2 | Wave Life Sciences USA, Inc. WVE | NCT04906460 Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) | Duchenne Muscular Dystrophy | active not recruiting | 25 |
| 2026-10 est. | P3 | Loxo Oncology, Inc. | NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | active not recruiting | 600 |
| 2026-10 est. | P2 | Gilead Sciences GILD | NCT05119907 Study of Sacituzumab Govitecan in Patients With Solid Tumor | Solid Tumor | active not recruiting | 53 |
| 2026-10 est. | P2 | Corcept Therapeutics CORT | NCT05407324 Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | active not recruiting | 279 |
| 2026-10 est. | P3 | AbbVie ABBV | NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | AMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNV | active not recruiting | 735 |
| 2026-10 est. | P3 | GIE Medical | NCT05561114 Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus | Esophageal Stricture | recruiting | 198 |
| 2026-10 est. | P2 | GEn1E Lifesciences | NCT05795465 A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, Acute | recruiting | 52 |
| 2026-10 est. | P3 | Industrial Farmacéutica Cantabria, S.A. | NCT05888922 Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia | Androgenetic Alopecia; Female Pattern Baldness | active not recruiting | 520 |
| 2026-10 est. | P2/P3 | Privo Technologies | NCT05893888 A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers | Oral Squamous Cell Carcinoma | recruiting | 40 |
| 2026-10 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06057922 A Study YL201 in Patients With Selected Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 990 |
| 2026-10 est. | P3 | Curium US LLC | NCT06235151 Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Prostate Cancer; Prostate Adenocarcinoma | active not recruiting | 439 |
| 2026-10 est. | P1/P2 | RinuaGene Biotechnology Co., Ltd. | NCT06273553 A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | Human Papillomavirus Associated Intraepithelial Neoplasia; Cervical Intraepithelial Neoplasia Grade | not yet recruiting | 39 |
| 2026-10 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06300177 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy | Non Small Cell Lung Cancer | recruiting | 522 |
| 2026-10 est. | P2/P3 | Biohaven Therapeutics Ltd. BHVN | NCT06309966 Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Focal Epilepsy | active not recruiting | 390 |
| 2026-10 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06316531 A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | HER2-positive Breast Cancer | active not recruiting | 274 |
| 2026-10 est. | P3 | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | NCT06403501 Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris | Acne Vulgaris | recruiting | 692 |
| 2026-10 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06423885 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocar | HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 64 |
| 2026-10 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06474468 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer | Advanced or Metastatic Esophageal Cancer | unknown | 148 |
| 2026-10 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | 248 |
| 2026-10 est. | P1/P2 | CanSino Biologics Inc. | NCT06577298 A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers | Poliomyelitis | active not recruiting | 480 |
| 2026-10 est. | P1/P2 | Biotheus Inc. | NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | HCC; Liver Cancer | not yet recruiting | 140 |
| 2026-10 est. | P3 | Akeso | NCT06591520 AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | Biliary Tract Cancer | active not recruiting | 682 |
| 2026-10 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06598787 A Study of BL-B01D1 in Patients With Recurrent Glioblastoma | Recurrent Glioblastoma | recruiting | 20 |
| 2026-10 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular | Advanced Hepatocellular Carcinoma | recruiting | 590 |
| 2026-10 est. | P1/P2 | Nimble Science Ltd. | NCT06702280 Assessing the Safety of an IGY Supplement on the Gut Microbiome | Healthy; Microbiome | withdrawn | |
| 2026-10 est. | P2 | Keymed Biosciences Co.Ltd | NCT06791772 Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) | Systemic Lupus Erythematosus | not yet recruiting | 150 |
| 2026-10 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2026-10 est. | P2/P3 | Ebima Clifford Okundaye | NCT06866236 Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression | Chronic Kidney Diseases; Acute Kidney Injury; Kidney Failure | not yet recruiting | 3000 |
| 2026-10 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06929325 Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibi | HR+/HER2- Advanced/Metastatic Breast Cancer | not yet recruiting | 312 |
| 2026-10 est. | P2 | Immunovant Sciences GmbH IMVT | NCT06980805 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | active not recruiting | 56 |
| 2026-10 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07090161 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | Hypertension; Uncontrolled Hypertension | recruiting | 240 |
| 2026-10 est. | P1/P2 | TYK Medicines, Inc | NCT07104617 Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC) | Metastatic Castration-resistant Prostate Cancer (mCRPC) | not yet recruiting | 48 |
| 2026-10 est. | P2 | ImmunityBio, Inc. IBRX | NCT07108036 A Study to Assess Anktiva in Patients With Long Covid-19. | Long COVID | recruiting | 20 |
| 2026-10 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer | CLDN18.2-positive Advanced Biliary Tract Cancer | not yet recruiting | 120 |
| 2026-10 est. | P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT07159243 Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | not yet recruiting | 180 |
| 2026-10 est. | P2 | Triveni Bio | NCT07167758 A Study Evaluating TRIV-509 in Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 95 |
| 2026-10 est. | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT07229729 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | recruiting | 300 |
| 2026-10 est. | P1/P2 | Shanghai Shengdi Pharmaceutical Co., Ltd | NCT07231211 A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | Solid Tumors | recruiting | 258 |
| 2026-10 est. | P2 | Lallemand Health Solutions | NCT07246161 Vaginal Detection of Orally Delivered Probiotic Strains in Healthy Women | Focus is on Healthy Subjects | recruiting | 72 |
| 2026-10 est. | P2 | Advagene Biopharma Co. Ltd. | NCT07250594 A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma | Eosinophilic Asthma | not yet recruiting | 126 |
| 2026-10 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07256782 A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 444 |
| 2026-10 est. | P3 | Senseye, Inc. | NCT07280065 REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool | PTSD - Post Traumatic Stress Disorder | recruiting | 1900 |
| 2026-10 est. | P1/P2 | Aramis Biotechnologies Inc. | NCT07291635 Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine | Influenza | active not recruiting | 728 |
| 2026-10 est. | P2 | Beijing Inno Medicine Co., Ltd. | NCT07311330 Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction | Atherosclerotic Cardiovascular Disease (ASCVD); Erectile Dysfunction | recruiting | 40 |
| 2026-10 est. | P2 | Disc Medicine, Inc IRON | NCT07368972 Study of DISC-0974-201 in Participants With IBD and Anemia | Inflammatory Bowel Disease (IBD); Anemia; Inflammatory Bowel Disease (IBD); Anemia | recruiting | 21 |
| 2026-10 est. | P2 | Housey Healthcare ULC | NCT07546929 HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes | Type 2 Diabetes | recruiting | 300 |
| 2026-10 est. | P2 | Chengdu Kangnuoxing Biopharma,Inc. | NCT07617324 Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) | Seasonal Allergic Rhinitis (SAR) | not yet recruiting | 15 |
| 2026-10 est. | P3 | Colgate Palmolive CL | NCT07625670 Clinical Study to Evaluate Remineralization Using an in Situ Model. | Remineralization; Enamel Lesions; Enamel Subsurface Lesion | enrolling by invitation | 30 |
| 2026-10 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07640451 A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | COPD | recruiting | 90 |
| 2026-10 est. | P2/P3 | Shanghai Huilun Pharmaceutical Co., Ltd. | NCT07699601 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery | Postoperative Pain | recruiting | 330 |
| 2026-10 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07706777 Clinical Study of HRS-2129 for Acute Gouty Arthritis | Acute Gouty Arthritis | recruiting | 90 |
| 2026-10 est. | P2/P3 | Shanghai Huilun Pharmaceutical Co., Ltd. | NCT07709598 Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery | Postoperative Pain | recruiting | 330 |
| 2026-10 est. | P2 | AbbVie ABBV | NCT07730554 A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants | Forehead Lines | active not recruiting | 84 |
| 2026-10 est. | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07791537 Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight | Overweight , Obesity | active not recruiting | 125 |
| 2026-10 est. | P2 | Taejoon Pharmaceutical Co., Ltd. | NCT07810972 Evaluate the Safety and Efficacy of TJO-087 | Dry Eye Syndrome (DES) | active not recruiting | 90 |
| 2026-10-01 | P1/P2 | Merus B.V. | NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and | terminated | 194 |
| 2026-10-01 est. | P1/P2 | USWM CT, LLC | NCT05642455 SPEARHEAD-3 Pediatric Study | Synovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma (NBL); Osteosarcoma | recruiting | 20 |
| 2026-10-01 est. | P2 | Taiho Oncology, Inc. | NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Ade | active not recruiting | 53 |
| 2026-10-01 est. | P3 | Novo Nordisk A/S NVO | NCT06200207 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Heart Failure; Systemic Inflammation | active not recruiting | 673 |
| 2026-10-01 est. | P3 | Beijing Dongfang Biotech Co., Ltd. | NCT06257966 A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin | Type2 Diabetes Mellitus | active not recruiting | 600 |
| 2026-10-01 | P2 | Incyte Corporation INCY | NCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | active not recruiting | 130 |
| 2026-10-01 est. | P2 | RemeGen Co., Ltd. | NCT06642545 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | Breast Cancer | recruiting | 40 |
| 2026-10-01 est. | P1/P2 | Kelifarma | NCT06678399 Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cell | Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery | not yet recruiting | 91 |
| 2026-10-01 est. | P1/P2 | Inhatarget Therapeutics | NCT06896890 Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | NSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancer | recruiting | 32 |
| 2026-10-01 | P3 | Incyte Corporation INCY | NCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Hidradenitis Suppurativa | active not recruiting | 573 |
| 2026-10-01 | P2 | Nuvig Therapeutics, Inc. | NCT07027111 Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 14 |
| 2026-10-01 est. | P2 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | NCT07188610 PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma | recruiting | 100 |
| 2026-10-01 est. | P1/P2 | Prana Therapies Inc | NCT07245368 Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Mild to Moderate Asthma | recruiting | 96 |
| 2026-10-01 | P2 | Qlaris Bio, Inc. | NCT07354477 Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation | Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (N | completed | 9 |
| 2026-10-01 est. | P2 | Research Institute of Geroprotective Technologies | NCT07397351 Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation | Coronary Artery Disease | recruiting | 180 |
| 2026-10-01 est. | P2 | BioRay Pharmaceutical Co., Ltd. | NCT07498647 Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia | Gout and Hyperuricemia | not yet recruiting | 160 |
| 2026-10-01 est. | P2 | Fujian Akeylink Biotechnology Co., Ltd. | NCT07709520 Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B | Chronic Hepatitis B | recruiting | 80 |
| 2026-10-01 | P1/P2 | AstraZeneca AZN | NCT07717840 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) | RSV Respiratory Syncytial Virus | active not recruiting | 164 |
| 2026-10-02 | P3 | SK Life Science, Inc. | NCT05067634 Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | Partial Epilepsy | completed | 154 |
| 2026-10-02 | P3 | MedTrace Pharma A/S | NCT05134012 RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) | Coronary Artery Disease | completed | 232 |
| 2026-10-02 est. | P1/P2 | PEACHES BIOTECH | NCT06684379 Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Co | SARS-CoV-2; Influenza, Human; Respiratory Syncytial Virus Infections; Respiratory Distress Syndrome; | recruiting | 50 |
| 2026-10-02 | P2 | Teva Branded Pharmaceutical Products R&D LLC | NCT06807463 A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease | Celiac Disease | active not recruiting | 50 |
| 2026-10-04 | P2 | Bausch & Lomb Incorporated BLCO | NCT07412496 A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy | Pain, Postoperative | completed | 130 |
| 2026-10-04 est. | P2 | Eddingpharm (Zhuhai) Co., Ltd. | NCT07489209 A Dose-exploration Study of EDP167 in HoFH | Homozygous Familial Hypercholesterolemia (HoFH) | recruiting | 20 |
| 2026-10-05 est. | P3 | Swedish Orphan Biovitrum | NCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofib | active not recruiting | 407 |
| 2026-10-05 est. | P1/P2 | ModernaTX, Inc. | NCT05164094 A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | Epstein-Barr Virus Infection | active not recruiting | 867 |
| 2026-10-05 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT05511363 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Psychosis Associated With Alzheimer's Disease | recruiting | 410 |
| 2026-10-05 | P2 | Hoffmann-La Roche | NCT05805501 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinom | Renal Cell Carcinoma | completed | 199 |
| 2026-10-05 | P2/P3 | UCB Biopharma SRL | NCT06149559 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | completed | 14 |
| 2026-10-05 | P2 | Ferrer Internacional S.A. | NCT06355531 A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | completed | 241 |
| 2026-10-06 | P3 | GlaxoSmithKline | NCT05263934 Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Eosinophilic Granulomatosis With Polyangiitis | completed | 163 |
| 2026-10-06 | P1/P2 | Pfizer PFE | NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-St | Breast Cancer | terminated | 20 |
| 2026-10-06 | P3 | ArriVent BioPharma, Inc. AVBP | NCT05607550 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal | Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations | active not recruiting | 398 |
| 2026-10-06 est. | P3 | Bristol-Myers Squibb BMY | NCT06003426 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | active not recruiting | 1255 |
| 2026-10-07 | P1/P2 | ModernaTX, Inc. | NCT05992935 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 8 | Norovirus Acute Gastroenteritis | completed | 1407 |
| 2026-10-08 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT07163364 A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) | Methylmalonic Acidemia (MMA) | not yet recruiting | 20 |
| 2026-10-09 | P3 | Regeneron Pharmaceuticals REGN | NCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Atopic Dermatitis | completed | 880 |
| 2026-10-09 | P3 | Debiopharm International SA | NCT06129539 A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial) | Central Precocious Puberty | active not recruiting | 56 |
| 2026-10-09 | P2 | Xentria, Inc. | NCT06169397 An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | completed | 31 |
| 2026-10-09 | P2 | Pfizer PFE | NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Stu | Pulmonary Hypertension | terminated | 42 |
| 2026-10-10 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07193459 Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes | recruiting | 360 |
| 2026-10-10 | P1/P2 | Chongqing Peg-Bio Biopharm Co., Ltd. | NCT07446491 A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure | Thrombocytopenia Associated With Chronic Liver Disease | completed | 54 |
| 2026-10-11 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT07083505 A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer | Advanced Breast Cancer | not yet recruiting | 60 |
| 2026-10-11 est. | P3 | Biocodex | NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome | IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptoms | recruiting | 406 |
| 2026-10-12 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT05372354 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refract | Multiple Myeloma | recruiting | 260 |
| 2026-10-12 est. | P3 | Janssen Research & Development, LLC | NCT05884398 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC | Metastatic Castrate-sensitive Prostate Cancer | active not recruiting | 420 |
| 2026-10-12 est. | P2 | Jiangsu Carephar Pharmaceutical Co., Ltd. | NCT07677514 A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease | Crohn's Disease | not yet recruiting | 156 |
| 2026-10-13 | P2 | AbbVie ABBV | NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-Related Macular Degeneration (nAMD) | active not recruiting | 146 |
| 2026-10-13 est. | P1/P2 | Aspa Therapeutics | NCT04998396 A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial) | Canavan Disease | recruiting | 26 |
| 2026-10-13 est. | P2 | Daewoong Pharmaceutical Co. LTD. | NCT05389215 Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | Idiopathic Pulmonary Fibrosis | active not recruiting | 102 |
| 2026-10-13 est. | P1/P2 | GlaxoSmithKline | NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrin | active not recruiting | 83 |
| 2026-10-13 est. | P3 | Shanghai JMT-Bio Inc. | NCT06846437 JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | recruiting | 228 |
| 2026-10-13 | P1/P2 | Voyager Therapeutics VYGR | NCT06874621 VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease | Alzheimer's Disease (AD) | active not recruiting | 52 |
| 2026-10-14 est. | P3 | Hoffmann-La Roche | NCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and B | Unresectable Hepatocellular Carcinoma | active not recruiting | 557 |
| 2026-10-14 | P3 | Organon and Co OGN | NCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | Plaque Psoriasis | completed | 58 |
| 2026-10-15 est. | P3 | Janssen Research & Development, LLC | NCT05702034 A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE | Ischemic Stroke; Ischemic Attack, Transient | active not recruiting | 12523 |
| 2026-10-15 | P2 | Hoffmann-La Roche | NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced | Breast Cancer | completed | 83 |
| 2026-10-15 | P3 | Novartis Pharmaceuticals NVS | NCT05900141 An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Hyperlipoproteinemia (a) | terminated | 41 |
| 2026-10-15 est. | P1/P2 | Eclipse Life Sciences, Inc. | NCT06536491 EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema | Diabetic Macular Edema | active not recruiting | 75 |
| 2026-10-15 est. | P3 | Suzhou Alphamab Co., Ltd. | NCT06569108 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors | Hemophilia A Without Inhibitor; Hemophilia B Without Inhibitor | active not recruiting | 125 |
| 2026-10-15 est. | P2 | Eccogene | NCT07505303 MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Adult Obesity; Weight Management | active not recruiting | 151 |
| 2026-10-15 | P3 | Dexa Medica Group | NCT07937449 The Efficacy and Safety of DLBS3233 in Adults With Prediabetes | Prediabetes | completed | 120 |
| 2026-10-16 | P3 | LEO Pharma | NCT06311682 A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic D | Atopic Dermatitis | recruiting | 195 |
| 2026-10-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT07033585 Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers | Type 2 Diabetes | active not recruiting | 600 |
| 2026-10-18 est. | P2 | Kunming Pharmaceuticals, Inc. | NCT07279493 Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke | Acute Ischemic Stroke | recruiting | 300 |
| 2026-10-19 est. | P3 | Bristol-Myers Squibb BMY | NCT05617677 A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | active not recruiting | 516 |
| 2026-10-19 est. | P3 | Bristol-Myers Squibb BMY | NCT05620407 A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 513 |
| 2026-10-19 | P3 | Merck Sharp & Dohme LLC MRK | NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Gastroesophageal Cancer | active not recruiting | 473 |
| 2026-10-19 est. | P3 | Incyte Corporation INCY | NCT06516952 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | Prurigo Nodularis | active not recruiting | 349 |
| 2026-10-19 | P1/P2 | Arsenal Biosciences, Inc. | NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | 3 |
| 2026-10-20 est. | P2/P3 | Biogen BIIB | NCT05531565 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | active not recruiting | 450 |
| 2026-10-20 est. | P1/P2 | Bioray Laboratories | NCT05577312 Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia | Beta-Thalassemia | active not recruiting | 39 |
| 2026-10-20 est. | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT06894212 A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia | Schizophrenia | active not recruiting | 538 |
| 2026-10-21 | P2 | Oruka Therapeutics, Inc. ORKA | NCT07290569 Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 160 |
| 2026-10-21 | P3 | Vaxcyte, Inc. PCVX | NCT07365826 A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | Pneumococcal Disease | completed | 1390 |
| 2026-10-22 est. | P3 | Hoffmann-La Roche | NCT03523858 A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | Progressive Multiple Sclerosis (PMS) | active not recruiting | 927 |
| 2026-10-22 | P1/P2 | Hoffmann-La Roche | NCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Non-Hodgkins Lymphoma | completed | 211 |
| 2026-10-22 est. | P3 | Amgen AMGN | NCT06245408 A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State | Sjögren's Syndrome (SS) | active not recruiting | 434 |
| 2026-10-22 | P3 | Eli Lilly and Company LLY | NCT06339008 A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) | Perennial Allergic Rhinitis (PAR) | active not recruiting | 450 |
| 2026-10-22 est. | P2 | Shanghai Henlius Biotech | NCT06812260 A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC | SCLC, Extensive Stage | active not recruiting | 26 |
| 2026-10-23 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06799559 Study on the Efficacy and Safety of QLM1016 in Schizophrenia | Schizophrenia | active not recruiting | 402 |
| 2026-10-23 est. | P2 | AstraZeneca AZN | NCT07017179 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight | Obesity/Overweight | active not recruiting | 16 |
| 2026-10-24 | P2 | Clear Scientific, Inc. | NCT06721494 A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine | Methamphetamine Intoxication; Methamphetamine Disorders; Methamphetamine Abuse | completed | 34 |
| 2026-10-25 | P3 | Vaxcyte, Inc. PCVX | NCT07425392 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | Pneumococcal Disease | completed | 752 |
| 2026-10-26 est. | P3 | Galderma R&D | NCT04204616 A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | Prurigo Nodularis | active not recruiting | 500 |
| 2026-10-26 est. | P3 | Novartis Pharmaceuticals NVS | NCT05360446 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in | Coronary Artery Disease | active not recruiting | 610 |
| 2026-10-26 | P2 | GlaxoSmithKline | NCT05565378 A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | Lung Cancer, Non-Small Cell | active not recruiting | 351 |
| 2026-10-26 | P3 | Eli Lilly and Company LLY | NCT06297603 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Ba | Type 2 Diabetes | active not recruiting | 341 |
| 2026-10-26 | P3 | Teva Branded Pharmaceutical Products R&D LLC | NCT06664619 A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and | Asthma | completed | 649 |
| 2026-10-26 | P2 | Boehringer Ingelheim | NCT06722157 A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Macular Degeneration, Age-related; Geographic Atrophy | completed | 202 |
| 2026-10-27 | P2 | Gilead Sciences GILD | NCT02932150 Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | active not recruiting | 150 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherap | Carcinoma, Non-Small-Cell Lung | active not recruiting | 103 |
| 2026-10-27 est. | P1/P2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT07449156 A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris. | Acne Vulgaris | not yet recruiting | 21 |
| 2026-10-28 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrec | Carcinoma, Renal Cell | active not recruiting | 1800 |
| 2026-10-28 est. | P3 | Albireo, an Ipsen Company | NCT05426733 An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia | Biliary Atresia | active not recruiting | 180 |
| 2026-10-28 | P2 | Genentech, Inc. | NCT06524375 A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic | Chronic Lymphocytic Leukemia | active not recruiting | 118 |
| 2026-10-28 est. | P3 | Akeso | NCT06617416 A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | NSCLC (Non-small Cell Lung Cancer) | recruiting | 560 |
| 2026-10-28 | P3 | Xenon Pharmaceuticals Inc. XENE | NCT06775379 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Major Depressive Disorder | terminated | 357 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-29 | P3 | Novartis Pharmaceuticals NVS | NCT05653349 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) | Primary Immune Thrombocytopenia (ITP) | active not recruiting | 226 |
| 2026-10-29 est. | P2 | RECORDATI GROUP | NCT05928390 Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia | Post-Bariatric Hypoglycemia | active not recruiting | 93 |
| 2026-10-29 | P2 | Acumen Pharmaceuticals ABOS | NCT06335173 A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) | Alzheimer Disease | active not recruiting | 542 |
| 2026-10-29 est. | P3 | Hoffmann-La Roche | NCT06588855 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulce | Moderately to Severely Active Ulcerative Colitis | active not recruiting | 350 |
| 2026-10-29 | P3 | Incyte Corporation INCY | NCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Hidradenitis Suppurativa | active not recruiting | 580 |
| 2026-10-29 | P2 | Tisento Therapeutics | NCT06961344 An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM) | Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) | terminated | 37 |
| 2026-10-30 est. | P2 | Genzyme, a Sanofi Company | NCT02843035 Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension | Gaucher Disease Type 1; Gaucher Disease Type 3 | active not recruiting | 12 |
| 2026-10-30 est. | P1/P2 | Nouscom SRL | NCT04041310 Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Solid Tumor, Adult | active not recruiting | 115 |
| 2026-10-30 est. | P3 | Pfizer PFE | NCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Melanoma | active not recruiting | 257 |
| 2026-10-30 est. | P3 | Laekna Limited | NCT04851613 Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Breast Cancer | active not recruiting | 256 |
| 2026-10-30 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05444257 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Cystic Fibrosis | active not recruiting | 822 |
| 2026-10-30 est. | P2 | Mirati Therapeutics Inc. | NCT05853575 Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung | active not recruiting | 200 |
| 2026-10-30 est. | P1/P2 | Biotheus Inc. | NCT05918133 A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | active not recruiting | 42 |
| 2026-10-30 est. | P2 | Abbisko Therapeutics Co, Ltd | NCT06186804 A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) | cGvHD | enrolling by invitation | 64 |
| 2026-10-30 | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT06415344 Long-term Extension of GTX-102 in Angelman Syndrome | Angelman Syndrome | terminated | 66 |
| 2026-10-30 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06679036 A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients | Advanced Unresectable or Metastatic Breast Cancer | recruiting | 300 |
| 2026-10-30 est. | P1/P2 | Shanghai Henlius Biotech | NCT06848699 A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | Solid Tumor Cancer; Non Small Cell Lung Cancer | recruiting | 105 |
| 2026-10-30 est. | P1/P2 | Antelope Surgical Solutions, Inc | NCT06906471 A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | Prostate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imaging | active not recruiting | 15 |
| 2026-10-30 est. | P1/P2 | Nuwacell Biotechnologies Co., Ltd. | NCT06941350 A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD | Acute Graft-versus-Host Disease | not yet recruiting | 24 |
| 2026-10-30 est. | P2 | Insud Pharma | NCT06968481 Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage | Post Partum Hemorrhage | not yet recruiting | 330 |
| 2026-10-30 | P1/P2 | Arvinas Inc. ARVN | NCT07023731 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | KRAS G12D Mutation; Advanced Solid Cancer | completed | 76 |
| 2026-10-30 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT07026968 A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes | Type 2 Diabetes | active not recruiting | 815 |
| 2026-10-30 est. | P1/P2 | Vidya Therapeutics Inc | NCT07085507 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients | Multiple Sclerosis | recruiting | 100 |
| 2026-10-30 | P2 | Ultragenyx Pharmaceutical Inc RARE | NCT07157254 A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) | Angelman Syndrome | terminated | 55 |
| 2026-10-30 | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT07251998 Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 182 |
| 2026-10-30 est. | P2 | Jiangxi Kvvit Pharmaceutical Co., Ltd. | NCT07345390 Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris | Acne Vulgaris | not yet recruiting | 180 |
| 2026-10-30 est. | P2 | Vincentage Pharma Co., Ltd | NCT07360275 A Study of VCT220 in Participants With Hypertension and Obesity or Overweight | Hypertension | active not recruiting | 160 |
| 2026-10-30 est. | P3 | Natureceuticals Sdn Bhd | NCT07669467 Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer | Fatigue Related to Cancer Treatment; Breast Cancer | recruiting | 250 |
| 2026-10-31 est. | P1/P2 | Orion Corporation, Orion Pharma ORN | NCT03436485 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | active not recruiting | 204 |
| 2026-10-31 est. | P2 | Astellas Pharma Global Development, Inc. | NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma | active not recruiting | 393 |
| 2026-10-31 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04842617 Phase III Study :SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage | active not recruiting | 5274 |
| 2026-10-31 est. | P1/P2 | LaNova Medicines Limited | NCT05518045 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 392 |
| 2026-10-31 est. | P2 | AskBio Inc | NCT05598333 Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure | Congestive Heart Failure | active not recruiting | 150 |
| 2026-10-31 est. | P1/P2 | Intralytix, Inc. | NCT05715619 Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects | Vancomycin-Resistant Enterococcal Colonization | suspended | 80 |
| 2026-10-31 est. | P2 | MaaT Pharma | NCT05762211 Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) | Transplant Complication | recruiting | 387 |
| 2026-10-31 est. | P3 | Olema Oncology, Inc. OLMA | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Neg | active not recruiting | 510 |
| 2026-10-31 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06083207 A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 116 |
| 2026-10-31 est. | P2 | NEXTGEN Bioscience | NCT06104839 Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata | Alopecia Areata | recruiting | 73 |
| 2026-10-31 est. | P2 | Kyowa Kirin Co., Ltd. | NCT06116916 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | active not recruiting | 185 |
| 2026-10-31 est. | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06222879 Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer | Breast Cancer | unknown | 350 |
| 2026-10-31 est. | P2 | Salubris Biotherapeutics Inc | NCT06369298 Study of JK07 in Patients With Chronic Heart Failure | Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction | active not recruiting | 282 |
| 2026-10-31 est. | P2 | Avistone Biotechnology Co., Ltd. | NCT06574347 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. | Non-Small-Cell Lung Cancer | recruiting | 120 |
| 2026-10-31 est. | P2 | Amgen AMGN | NCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | MTAP-deleted NSCLC | active not recruiting | 61 |
| 2026-10-31 est. | P3 | AstraZeneca AZN | NCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients | Breast Cancer | active not recruiting | 293 |
| 2026-10-31 est. | P3 | Longboard Pharmaceuticals | NCT06719141 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | Developmental and Epileptic Encephalopathy | active not recruiting | 367 |
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06742892 A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy | Carcinoma, Hepatocellular | recruiting | 90 |
| 2026-10-31 est. | P2 | Shanghai Henlius Biotech | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy | Esophageal Cancer | recruiting | 102 |
| 2026-10-31 est. | P2 | Topadur Pharma AG | NCT06954597 Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis | Digital Ulcers in Systemic Sclerosis | recruiting | 15 |
| 2026-10-31 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07019090 Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | not yet recruiting | 120 |
| 2026-10-31 est. | P2 | Animuscure Inc. | NCT07072195 A Study of AMC6156 in People With Sarcopenia | Sarcopenia in Elderly; Sarcopenia | recruiting | 80 |
| 2026-10-31 est. | P2 | Spyre Therapeutics, Inc. SYRE | NCT07148414 A Study of SPY072 in Rheumatic Disease | Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Jo | active not recruiting | 285 |
| 2026-10-31 est. | P1/P2 | Myosin Therapeutics Inc. | NCT07185880 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients | Glioblastoma (GBM) | recruiting | 36 |
| 2026-10-31 est. | P3 | TG Therapeutics, Inc. TGTX | NCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing | Relapsing Multiple Sclerosis | active not recruiting | 360 |
| 2026-10-31 est. | P2 | Neurimmune AG | NCT07213583 Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Amyloid Transthyretin Cardiomyopathy | active not recruiting | 35 |
| 2026-10-31 est. | P2 | Changzhou Qianhong Bio-pharma Co., Ltd. | NCT07396337 Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. | Acute Ischemic Stroke | recruiting | 320 |
| 2026-10-31 est. | P2 | Kadence Bio | NCT07434271 Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Pr | Premature Ejaculation | recruiting | 40 |
| 2026-10-31 est. | P2 | Freya Biosciences ApS | NCT07453069 Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle | Vaginal Dysbiosis | recruiting | 30 |
| 2026-10-31 est. | P3 | Natureceuticals Sdn Bhd | NCT07669454 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in | Fatigue Related to Cancer Treatment; Colon Cancer | recruiting | 250 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.